Results 201 to 210 of about 255,779 (244)

Myeloid-derived PD-L1 characterizes spatially organized immune architecture in colorectal cancer. [PDF]

Front Immunol
Wu Q, Tissot S, Peddle A, Yin K, Sagaert X, De Hertogh G, Abdelkader B, Pu T, Van Herpe F, D'Hoore A, Rusakiewicz S, Verbandt S, Tejpar S, Rasschaert G.   +13 more
europepmc   +1 more source

Therapeutic Gases in Biomedicine: Updates on Nitric Oxide and Beyond

Advanced Science, EarlyView.
Therapeutic gases, including NO, CO, H2S, H2, CO2, O2, and Xe, play vital roles in cellular signaling and repair. This review highlights the emerging carriers and delivery systems that enable controlled, localized gas release for diagnostic and therapeutic applications.
Syed Muntazir Andrabi, Navatha Shree Sharma, Imran Ibn Gani Rather, S. M. Shatil Shahriar, Jingwei Xie   +4 more
wiley   +1 more source

Erratum: Ginseng-Derived Exosomes Attenuate Immune Evasion in NSCLC via PD-L1 Modulation [Corrigendum]. [PDF]

Cancer Manag Res
europepmc   +1 more source

Correction: Endocrine advantages of PD-1/PD-L1 therapy: Comparative analysis of FAERS-JADER. [PDF]

PLoS One
Gao Y, Jiang S, Cui Y, Wang Y, Yu L.
europepmc   +1 more source

PRELID1 and VDAC3 Coordinate a Senescence‐Like State in Germinal Center B Cells to Promote IL‐7–Driven Antitumor Immunity in Colorectal Cancer

Advanced Science, EarlyView.
Colorectal cancer is characterized by an immunosuppressive microenvironment that limits immunotherapy efficacy. We identify a senescence‐like state in germinal center B cells driven by the PRELID1–VDAC3 axis, which promotes IL‐7 secretion, alleviates CD8+ T‐cell exhaustion, and enhances antitumor immunity. Targeting this pathway improves responsiveness
Yuhan Liao, Huimeng Xu, Xinghua Zhuo, Shupeng Hu, Lanhui Huang, Zhe Hao, Jianxiong Chen, Yulu Wang, Jun Zhou   +8 more
wiley   +1 more source

Immunotherapy for Glioblastoma: A Focus on PD-1/PD-L1 Inhibitors. [PDF]

Cancers (Basel)
Zoi V, Galani V, Sioka C, Alexiou GA, Kyritsis AP.   +4 more
europepmc   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

Advanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang, Xuan Wang, Xinfeng Dai, Linxin Tian, Wencheng Shen, Xueliang Liu, Wei Xue, Jiahua Pan, Yu Yang   +8 more
wiley   +1 more source

Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression. [PDF]

J Immunother Cancer
Liu S, Jiang Y, Fu Y, Wang S, Fu R, Gao M, Zhao Y, Chen S, Yang Y, Yang W, Jia L, Qin M, Zhang X, Cui W, Wang L.   +14 more
europepmc   +1 more source